Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Apr
11
2012
New Title Insurance Designed Specifically for Energy Projects McDermott Will & Emery
Jan
12
2013
Section 102(g) Is Still Available as a Defense for Pre-AIA Patents McDermott Will & Emery
May
17
2021
European Commission and National Authorities Take a Stand Against Excessive Pricing by the Pharmaceutical Industry McDermott Will & Emery
Jul
18
2013
California Proposes Energy Storage Procurement Requirement McDermott Will & Emery
Aug
1
2013
Federal Circuit Has Appellate Jurisdiction Over International Trade Commission's (ITC) Dismissal of Claim Based on Arbitration Agreement McDermott Will & Emery
Aug
28
2018
Tribal Immunity Does Not Apply to IPR Proceedings McDermott Will & Emery
Sep
16
2021
Material Information Submitted to FDA but Withheld from PTO Gives Rise to Inequitable Conduct McDermott Will & Emery
Dec
10
2018
OIG Dusts off the Old Rule Book to Say No to Free Expensive Drugs to Hospitals McDermott Will & Emery
Mar
18
2014
Massachusetts Permit for New Natural Gas Plant Incorporates Global Climate Conditions Including Sunset Date McDermott Will & Emery
Dec
10
2021
FDA Issues Draft Guidance On the Use and Curation of Real-World Data in Registries McDermott Will & Emery
Dec
16
2021
Rounding Error: Intrinsic Evidence Informs Plain and Ordinary Meaning McDermott Will & Emery
Jan
8
2019
FDA 2018 Year in Review: Medical Devices McDermott Will & Emery
May
1
2014
Pre-Patent Issuance Activities Can Create Justiciable Controversy McDermott Will & Emery
Feb
15
2022
Treasury Responds to Biden Administration Executive Order With Report, Recommendations to Increase Alcohol Industry Competition [VIDEO] McDermott Will & Emery
Aug
3
2014
Dissent at the Patent Trial and Appeal Board (PTAB) Leads to … Unpatentability McDermott Will & Emery
Dec
30
2014
Reissue Patents Must Be Drawn to the Same Invention as the Original Patent McDermott Will & Emery
Feb
4
2015
FDA Issues Draft Guidance on General Wellness Devices and on Medical Device Accessories McDermott Will & Emery
Jun
21
2019
Key Changes in HELP’s Updated Lower Health Care Costs Act McDermott Will & Emery
May
7
2015
340B ‘Mega-Guidance’ Arrives at Office of Management and Budget McDermott Will & Emery
Jun
17
2015
Proposed Rules Released Covering 340B Ceiling Prices and Manufacturer Penalties McDermott Will & Emery
Sep
10
2015
FDA Releases Long-Awaited Biological Naming Draft Guidance and Proposed Rule McDermott Will & Emery
Oct
24
2019
Focus On Innovation Centers: Due Diligence For Collaborative Ventures McDermott Will & Emery
Nov
1
2019
McDermottPlus Check-Up: November 1, 2019 McDermott Will & Emery
Feb
28
2023
This Week in 340B: February 21 – 27, 2023 McDermott Will & Emery
Jan
15
2020
Modernizing FDA’s Data Strategy: Agency Announces March 27 Public Meeting, Requests Written Comments by End of April McDermott Will & Emery
Feb
12
2016
TTB Issues Ruling on Category Management under Federal Tied-House Statute McDermott Will & Emery
Jan
29
2020
No En Banc Review of Non-Institution Decision After Remand of Partial Institution McDermott Will & Emery
Feb
3
2020
CMS’s Healthy Adult Opportunity: What You Need to Know McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins